

Information disclosure is an essential prerequisite for running a pharmaceutical business nowadays. It is its culture. The interaction between pharmaceutical companies and health care professionals and organizations should become more transparent and clearer for patients, government institutions, and the wider public.

Every pharmaceutical company that is a member of the Association of International Pharmaceutical Manufactures (AIPM) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) has a duty to provide information about items of value, transferred directly or indirectly for the benefit of healthcare professionals and organizations.

According to the requirements of the EFPIA Code on Documentary proof and on Disclosure of transfers of value from pharmaceutical companies to healthcare professionals and healthcare organizations, adopted by the EFPIA Statutory General Assembly in June, 2013 (EFPIA Code), the Code of Marketing Practices of the Association of International Pharmaceutical Manufactures (AIPM Code), EFPIA and AIPM pharmaceutical member companies have a duty to disclose information regarding items of value that are transferred directly or indirectly for the benefit of healthcare organizations, every year within six months from the end of the full calendar year (accounting period).

We disclose transfers of values to healthcare professionals and healthcare organizations according to our liability against the EFPIA Code on Disclosure and corresponding local codes of good practice and/or local legal requirements, and according to Data Protection Regulations (including but not limited to Directive No. 95/46/EC of the European Union “On the protection of individuals with regard to the processing of personal data and on the free movement of such data” and local legislation).

As the divisions of Astellas in the Russian Federation are affiliates of AIPM and EFPIA member companies, and in performing their activities they meet the requirements of the above-mentioned Codes, as well as share the views of the above-mentioned associations, starting from 2016, the Astellas company will disclose information in accordance with the established procedure and scope.

The information on payments for the benefit of healthcare professionals and organizations will be disclosed in the following categories:

1. Donations and grants in support of healthcare;
2. Covering expenses related to holding events. Covering expenses related to holding events staged by healthcare organizations or third parties, including support for healthcare professionals at congresses, such as:
  - Registration fees;
  - Sponsorship agreements with healthcare organizations or third parties engaged by a healthcare organization for holding the event;
  - Travel and living costs.

### 3. Service and consulting fees.

We understand that the disclosure of information in respect of any agreements with our partners may be restricted. Therefore, any information disclosure may only be permitted with the individual's consent. According to the law, any organization or healthcare professionals are entitled at any time to refuse to give consent, or to withdraw consent already given. In such a case, information on the payments received will be disclosed in the form of a total amount and on a non-attributable basis.

Astellas undertakes to ensure full financial transparency in our industry and to enhance public confidence in relations between pharmaceutical companies and Healthcare Professionals.

The first information disclosure was made on 30 June 2016, and includes data on all relevant payments and expenses made in 2015. This and further information is available on our website: <http://www.astellas.ru/en/transparency/>